NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
OTTW Ottawa Savings Bancorp Inc
HMC Honda Motor Co Ltd
PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024
FFBW Ffbw Inc
CIB Bancolombia SA
TARA Protara Therapeutics Inc
SLAMU Slam Corp
SY So-Young International Inc
BHR Braemar Hotels & Resorts Inc

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
Day's Change
-0.04 (-1.09%)
B/A Size
Day's High
Day's Low

10-day average volume:

10-, 30-year Treasury yields hit lowest levels in a week as investors seek safety in government bonds

4:33 pm ET May 19, 2022 (MarketWatch)

By Vivien Lou Chen and William Watts

Investors flocked to Treasurys on Thursday, driving the 10- and 30-year yields to one-week lows, amid a continued stock selloff on stagflation fears that deepened this year's double-digit losses for all three major indexes.

What are yields doing

What's driving the market

Global equities slid Thursday and U.S. stock indexes finished lower, extending Wednesday's brutal selloff that left the Dow Jones Industrial Average down by 1,164.52 points, or 3.6%, and the S&P 500 lower by 4% --- their biggest one-day declines since June 11, 2020.

Growing fears of a stagflationary environment --- a combination of persistent inflation and stagnant economic growth -- continued to reverberate in markets on Thursday, a day after disappointing results from retailer Target Corp. (TGT) showed rising costs cutting more deeply into profits than many expected.

See:Next big shoe to drop in financial markets: Inflation that fails to respond to Fed rate hikes

In an interview with CNBC on Thursday, Kansas City Fed President Esther George said the "rough week in the equity markets" doesn't alter her support for half-point interest-rate hikes to cool inflation.Data released on Thursday showed that initial jobless claims rose to a four-month high of 218,000 last week, but most of the increase appeared tied to just a few states such as Kentucky and California. Claims had been expected to come in at a seasonally adjusted 200,000 for the week that ended May 14, according to economists surveyed by The Wall Street Journal.

The Philadelphia Fed manufacturing index fell sharply to 2.6 in May from 17.6 in the prior month, the lowest level of activity in two years. Economists polled by The Wall Street Journal had expected a 15 reading. Nonetheless, any reading above zero still indicates expansion in the manufacturing sector.Existing home sales dropped for a third straight month in April, falling 2.4% to a seasonally adjusted annual rate of 5.61 million.

What analysts are saying

"Investors have become increasingly concerned the market is overtightening for the Fed before the Committee has even brought rates back to neutral," said BMO Capital Markets strategists Ian Lyngen and Ben Jeffery.

"At the end of the day, the simple characterization of the price action of the last couple weeks is that the market is testing the Fed's resolve," they wrote in a note. "A more cynical interpretation would be investors are attempting to call the Fed's bluff, although we're less convinced of this narrative.""Whether this is 'the' moment that an equity correction undermines the wealth effect is a moot point," Lygen and Jeffery said. "If it isn't now, this episode will linger in the background as an inhibition to going all-in on stocks as policy becomes restrictive."

-Vivien Lou Chen


(END) Dow Jones Newswires

May 19, 2022 16:33 ET (20:33 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.